Brief: Abl Bio Inc Signs Agreement With Intocell Inc To Use Its Antibody-Drug Conjugate Tech In Product Development
23/10/2024 03:10
ABL Bio Inc 298380.KQ :
* ABL BIO INC: SIGNS AGREEMENT WITH INTOCELL INC TO USE ITS
ANTIBODY-DRUG CONJUGATE TECH IN PRODUCT DEVELOPMENT
Source text for Eikon: ID:
Further company coverage: 298380.KQ
Recent news on ABL Bio
See all newsBrief: Abl Bio Inc - Raises 37.7 Billion Won Worth Of New Shares
Brief: Abl Bio Announces Grabody-B Brain Delivery Platform License Agreement With GSK To Develop Novel Medicines For Neurodegenerative Diseases
Brief: Abl Bio Inc Signs Agreement With Intocell Inc To Use Its Antibody-Drug Conjugate Tech In Product Development
Brief: I-Mab And Abl Bio Announce Latest Updates Of Pd-L1 And 4-1BB Bispecific Antibody TJ-L14B/ABL503
Brief: Abl Bio To Acquire Real Estate Worth 65 Billion Won